000 03929cam a2200589Ii 4500
001 ocn898423398
003 OCoLC
005 20190328114810.0
006 m o d
007 cr |||||||||||
008 141220t20152015enka ob 000 0 eng d
010 _a 2014957608
040 _aEBLCP
_beng
_erda
_epn
_cEBLCP
_dN$T
_dOCLCQ
_dYDXCP
_dOPELS
_dOCLCF
_dMMU
_dOCLCO
_dCHVBK
_dOCLCQ
_dCNCGM
_dOCLCO
_dMERER
_dOCLCO
_dOCLCQ
_dOCLCA
_dU3W
_dOCLCO
_dD6H
_dOCLCQ
_dAU@
_dOCLCO
_dOCLCQ
_dWYU
_dCUY
_dLOA
_dZCU
_dUSU
_dMERUC
_dOCLCO
_dICG
_dK6U
_dCOCUF
_dOCLCQ
_dVT2
_dDKC
019 _a899567948
_a904419910
_a1088981102
020 _a9780081003473
_q(electronic bk.)
020 _a0081003471
_q(electronic bk.)
020 _z9780081003466
_q(print)
020 _z0081003463
_q(print)
035 _a(OCoLC)898423398
_z(OCoLC)899567948
_z(OCoLC)904419910
_z(OCoLC)1088981102
050 4 _aRM263
060 4 _aQV 267
072 7 _aMED
_x071000
_2bisacsh
082 0 4 _a615.58
_223
100 1 _aLu, Da-Yong,
_d1962-
_eauthor.
245 1 0 _aPersonalized cancer chemotherapy : an effective way of enhancing outcomes in clinics /
_h[electronic resource]
_cDa-Yong Lu.
264 1 _aCambridge, UK :
_bElsevier/Woodhead Publishing,
_c[2015]
264 4 _c�2015
300 _a1 online resource (85 pages) :
_billustrations (some color).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aWoodhead Publishing series in biomedicine ;
_v720
504 _aIncludes bibliographical references.
505 0 _aIntroduction -- Drug sensitivity testing -- Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection -- Pharmacogenetics -- Individualized antimetastatic therapy [1-2] -- Drug combinations -- Assistant chemotherapy -- Cost-effectiveness considerations -- Discussion -- Conclusion.
520 _aIndividualized cancer chemotherapy (ICC) has been designed to meet the requirement of selecting anticancer drugs in clinics and attracting increasing attentions in medical circle and will show more beneficial outcome in the future if we stick on these researches. Personalized Cancer Chemotherapy addresses and reviews this issue by discussing many existing specific strategies of ICC, including drug sensitivity testing, cancer biomarker detections, cancer biomarker-oriented therapy, anticancer drug pharmacogenetics, cancer metastasis therapy, anticancer drug combinations, assistant therapy, mathematics, and computational analysis of cancer malignancy and drug responses, cost effective and finally studies of relationship between different ICC strategies. The relationship between drug response and these techniques or methods is in-depth analyzed, discussed and highlight. Many longstanding key debates and future trends are also intensively discussed, highlighted and debuted with new twists.
588 0 _aOnline resource; title from electronic title page (ebrary, viewed on April 3, 2015).).
650 0 _aChemotherapy.
650 0 _aCancer
_xTreatment.
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aCancer
_xTreatment.
_2fast
_0(OCoLC)fst00845538
650 7 _aChemotherapy.
_2fast
_0(OCoLC)fst00853595
650 1 2 _aNeoplasms
_xdrug therapy.
_0(DNLM)D009369Q000188
650 2 2 _aAntineoplastic Agents.
_0(DNLM)D000970
650 2 2 _aDrug-Related Side Effects and Adverse Reactions.
_0(DNLM)D064420
650 2 2 _aPharmacogenetics
_xmethods.
_0(DNLM)D010597Q000379
650 2 2 _aPrecision Medicine
_xmethods.
_0(DNLM)D057285Q000379
655 4 _aElectronic books.
655 7 _aElectronic books.
_2lcgft
776 0 8 _iPrint version:
_tPersonalized Cancer Chemotherapy.
_dWoodhead Pub Ltd 2014
_z9780081003466
_w(DLC) 2014957608
_w(OCoLC)898160939
830 0 _aWoodhead Publishing series in biomedicine ;
_vno. 720.
_x2050-0289
856 4 0 _3ScienceDirect
_uhttp://www.sciencedirect.com/science/book/9780081003466
999 _c247030
_d247030